Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $10.51, but opened at $12.98. Evolus shares last traded at $13.57, with a volume of 865,474 shares changing hands.
Wall Street Analyst Weigh In
EOLS has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Tuesday.
Get Our Latest Report on Evolus
Evolus Stock Performance
The stock's 50 day moving average is $11.67 and its 200 day moving average is $13.74. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm has a market cap of $853.57 million, a price-to-earnings ratio of -14.81 and a beta of 1.32.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in shares of Evolus by 27.3% during the second quarter. Rhumbline Advisers now owns 81,439 shares of the company's stock worth $884,000 after buying an additional 17,442 shares in the last quarter. Sei Investments Co. increased its position in Evolus by 9.8% during the second quarter. Sei Investments Co. now owns 33,802 shares of the company's stock worth $367,000 after acquiring an additional 3,020 shares during the period. Profund Advisors LLC acquired a new stake in Evolus in the 2nd quarter worth about $130,000. Lombard Odier Asset Management USA Corp bought a new stake in Evolus in the 2nd quarter valued at about $246,000. Finally, Cubist Systematic Strategies LLC grew its position in shares of Evolus by 5.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 338,254 shares of the company's stock worth $3,670,000 after purchasing an additional 18,157 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Stories
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
